Разработка и регистрация лекарственных средств (Jan 2019)
THE STUDY OF EFFECTS OF THE INTRANASAL DEXMEDETOMIDINE ADMINISTRATION ON PAIN SENSITIVITY
Abstract
The development of new antinociceptive agents and new approaches to pain relief based on potent non-narcotic analgesics is one of the most in demand and urgent directions of modern pharmacology. This work substantiates the choice of the clinically most relevant representative of non-narcotic analgesics from the α2-adrenoreceptor agonist class - dexmedetomidine, which acts at low doses and demonstrates high therapeutic index for various modes of administration. An analgesic efficacy of dexmedetomidine in single intranasal administration of the original experimental pharmaceutical formulation was evaluated in models of acute thermal and visceral pain in laboratory animals (female outbred white mice). A pronounced dose-dependent analgesic effect of the dexmedetomidine preparation in the 10 and 50 μg/kg dosage was revealed in the test models of visceral pain. The analgesic effect of dexmedetomidine was accompanied by a dose-dependent sedative (but not anesthetic) effect in mice, with peak at 30 minutes for intranasal administration of 50 μg/kg of drug. In the doses used, dexmedetomidine did not exert any acute toxic effects in mice.
